Pays: Canada
Langue: anglais
Source: Health Canada
DONEPEZIL HYDROCHLORIDE
PHARMAPAR INC
N06DA02
DONEPEZIL
10MG
TABLET
DONEPEZIL HYDROCHLORIDE 10MG
ORAL
30/100
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0131548002; AHFS:
CANCELLED POST MARKET
2022-07-29
PRODUCT MONOGRAPH PR PRIVA-DONEPEZIL Donepezil Hydrochloride Tablets, House Std. 5 mg and 10 mg CHOLINESTERASE INHIBITOR PHARMAPAR INC. DATE OF REVISION: 1565 boul. Lionel-Boulet September 21, 2020 Varennes, Quebec J3X 1P7 SUBMISSION CONTROL NO.: 242839 _Priva-DONEPEZIL _ _Page 2 of 49 _ TABLE OF CONTENTS PAR T I: HEALTH PROFESSIONAL INFORMATION ..................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................................3 INDICATIONS AND CLINICAL USE .......................................................................................3 CONTRAINDICATIONS .............................................................................................................3 WARNINGS AND PRECAUTIONS ...........................................................................................3 ADVERSE REACTIONS .............................................................................................................7 DRUG INTERACTIONS ............................................................................................................15 DOSAGE AND ADMINISTRATION ........................................................................................17 OVERDOSAGE ..........................................................................................................................17 ACTION AND CLINICAL PHARMACOLOGY ......................................................................18 STORAGE AND STABILITY ...................................................................................................21 DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................................21 PAR T II: SCIENTIFIC INFORMATION ...........................................................................22 PHARMACEUTICAL INFORMATION ...................................................................................22 CLINICAL TRIALS ........................................................................................ Lire le document complet